LIPLASOME PHARMA ApS: Financial statements 2022
CVR: 29428514
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 2,202,000 and a net result of DKK 2,196,000 compared with DKK 98,000 the year before. That is an increase of 1,938.9% compared with the year before. Equity in the 2022 report amounted to DKK 2,371,000. The solvency ratio was 99.5%.
- Gross Profit
- DKK 2,202,000
- Profit/Loss
- DKK 2,196,000
- Equity
- DKK 2,371,000
- Total Assets
- DKK 2,383,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 2.2 mio. | 2.2 mio. | 2.4 mio. | - |
| 2021 | - | 108 t. | 98 t. | 175 t. | - |
| 2020 | - | -133 t. | -156 t. | 77 t. | - |
| 2019 | - | -81 t. | -33.6 mio. | 233 t. | - |
| 2018 | - | -61 t. | -54 t. | 33.8 mio. | - |
Official annual report
Keep an eye on LIPLASOME PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 14, 2022, BAGGER-SØRENSEN & CO. A/S is registered as an owner of LIPLASOME PHARMA ApS with an ownership share of 90%.
LIPLASOME PHARMA ApS has published its annual report for 2021. Gross profit came to DKK 108,000, and the net result was DKK 98,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named BIO-BEDST ApS. The management consists of Hans-Henrik Horsted Eriksen. The board consists of John Riis Mortensen (chair), Hans-Henrik Horsted Eriksen and Sanjay Kumar Sehgal. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity in the 2025 report amounted to DKK 2,377,000.